| Autor: |
Cherniawsky HM; University of Alberta, Edmonton, Alberta., Kukreti V; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON., Reece D; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON., Masih-Khan E; Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada; Canadian Myeloma Research Group, Toronto, Ontario. Esther.masih-khan@uhnresearch.ca., McCurdy A; The Ottawa Hospital, Ottawa, Ontario., Jimenez-Zepeda VH; Tom Baker Cancer Centre, Calgary, Alberta., Sebag M; Department of Oncology, Division of Hematology, McGill University, Montreal, QC., Song K; BC Cancer, Vancouver General Hospital, British Columbia., White D; Queen Elizabeth II Health Sciences Centre. Dalhousie University, Halifax, Nova Scotia., Stakiw J; Saskatoon Cancer Centre, University of Saskatchewan, Saskatoon, Saskatchewan., LeBlanc R; Maisonneuve-Rosemont Hospital Research Centre, University of Montreal, Montreal, Quebec., Reiman A; Department of Oncology, Saint John Regional Hospital, Saint John, NB., Aslam M; Allan Blair Cancer Centre, Regina, Saskatchewan., Louzada M; London Regional Cancer Center, London, Ontario., Kotb R; Cancer Care Manitoba, Winnipeg, Manitoba., Gul E; Canadian Myeloma Research Group, Toronto, Ontario., Atenafu E; Canadian Myeloma Research Group, Toronto, Ontario., Venner CP; Cross Cancer Institute, University of Alberta, Edmonton, Alberta. |
